Articles related to Pharmacy (Community)

Benzodiazepine use among U.S. adults aged 65 years and older declined before 2020 but remained largely unchanged through 2024. Long-term use persisted in roughly one-third of users, with smaller reductions among adults aged 75 years and older.

The FDA issued a Class II recall for an amphetamine-based ADHD medication after a labeling mix-up resulted in immediate-release capsules being packaged as extended release. The recall affects a single lot totaling 1,392 bottles.

Medicare’s new GLP-1 Bridge Program expands lower-cost access to certain weight-loss medications for eligible beneficiaries. Concurrent ISMP guidance outlines common medication errors and counseling challenges as more patients initiate GLP-1 therapy.

The FDA has approved the first generic version of baloxavir marboxil, a single-dose influenza antiviral noninferior to oseltamivir, ahead of the 2026-2027 flu season.

The FDA expanded approval of Capvaxive, a pneumococcal 21-valent conjugate vaccine, to children and adolescents aged 2 to 17 years with at least one chronic medical condition increasing pneumococcal disease risk, based on STRIDE-13 trial data showing noninferiority to PPSV23 across 12 shared serotypes and statistically significantly higher OPA GMTs for 9 serotypes unique to Capvaxive.

ASHP urged HRSA in a June 2 letter to take immediate enforcement action against Eli Lilly after the manufacturer gave an initial group of 340B-covered entities five business days to submit detailed claims-level data or lose access to discounted pricing across its full drug portfolio, including in-house hospital pharmacy dispensing and medically administered products; as of mid-June, the threatened cutoffs had not yet taken effect for many affected entities.